The National Comprehensive Cancer Network® (NCCN®) has released the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. The updated recommendations point to two booster vaccine doses for people who are immunocompromised (meaning three primary mRNA doses plus two booster doses).
“This guidance is intended to let cancer care providers know not only what they can do, but also what they should do, according to experts across the United States,” said Brahm Segal, MD, of Roswell Park Comprehensive Cancer Center, Co-Leader of the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis.
The latest update includes:
The committee continues to recommend that household members and other close contacts of people with cancer should get vaccinated according to their determined eligibility (per the Centers for Disease Control and Prevention).
“Bottom line, we want to share COVID-19 recommendations that are simple and useful,” said committee co-leader Lindsey R. Baden, MD, Professor of Medicine at Harvard Medical School and an infectious diseases specialist at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. “We know a lot more about COVID-19 and the vaccines now, and we can use that knowledge to minimize the confusion and enhance the protection we can offer to our immunocompromised patients.”
The NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis is comprised of leading multidisciplinary physicians from across NCCN’s member institutions, with particular expertise in infectious diseases, vaccine development and delivery, cancer management, and medical ethics. The group first published guidance on vaccinating people with cancer against COVID-19 in January of 2021 and has published numerous updates since then. The recommendations reflect the policies that have already been put in place in many of the country’s top academic cancer centers.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.